A Case of Primary Gastric Small-Cell Carcinoma in an Elderly Patient  by Yu, Fa-Chang et al.
at SciVerse ScienceDirect
International Journal of Gerontology 6 (2012) 49e51Contents lists availableInternational Journal of Gerontology
journal homepage: www.i jge-onl ine.comCase Report
A Case of Primary Gastric Small-Cell Carcinoma in an Elderly Patientq
Fa-Chang Yu 1, Ming-Jong Bair 2*, Huan-Lin Chen 2, I.-Tsung Lin 2, Chia-Hsien Wu 2, Yu-Shan Yen 3
1Department of Internal Medicine, MackayMemorial Hospital, Taipei, 2Division of Gastroenterology, Department of Internal Medicine, Mackay Memorial Hospital, Mackay Medicine,
3Department of Pathology, Mackay Memorial Hospital, Mackay Medicine, Taitung, Taiwana r t i c l e i n f o
Article history:
Received 23 February 2010
Received in revised form
19 May 2010
Accepted 25 September 2010
Available online 23 March 2012
Keywords:
elderly,
poor prognosis,
small-cell carcinoma,
stomachq All contributing authors declare no conﬂict of int
* Correspondence to: Dr Ming-Jong Bair, 1 Lane 30
Taiwan.
E-mail address: a5963@ttms.mmh.org.tw (M.-J. Ba
1873-9598/$ e see front matter Copyright  2012, Ta
doi:10.1016/j.ijge.2012.01.001s u m m a r y
We report a case of primary small-cell carcinoma of the stomach in a 75-year-old man. The patient was
admitted to our hospital with a 1-week history of intermittent tarry stool. An upper gastrointestinal
examination revealed a large stage A2 ulcer in the greater curvature of the body of the stomach, and
pathological ﬁndings from biopsy specimens revealed small-cell carcinoma. The tumor cells were small-
sized, composed of hyperchromatic nuclei with scant cytoplasm, and stained positive for cytokeratin,
synaptophysin, and chromogranin A. The patient was diagnosed with primary small-cell carcinoma of
the stomach. He declined further evaluation and received palliative management. This is a rare carci-
noma of the stomach, with aggressive manifestations and a poor prognosis. The mean survival of patients
with primary gastric small-cell carcinoma is reported to be 7 months. The choice of treatment for this
disease is still controversial. This rare gastric tumor should be listed in the differential diagnosis of gastric
carcinoma in the elderly.
Copyright  2012, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. All rights reserved.1. Introduction
Primary small-cell carcinoma (SmCC) of the stomach is a rare
neoplasm, accounting for 0.1% of all gastric cancers1,2. This tumor is
extremely aggressive, with a poor prognosis after diagnosis3. The
mean survival of patient with primary gastric SmCC is reported to
be 7 months2, but the therapeutic value of surgery or systemic
chemotherapy has not been conclusively proven4e6. In this report,
we describe a patient with advanced primary SmCC of the stomach,
diagnosed preoperatively, and analyze the clinicopathological
characteristics of this tumor in light of recently published literature.
2. Case report
A 78-year-old male had been undergoing treatment for
congestive heart failure (New York Heart Association functional
class II), chronic ischemic heart disease, and atrial ﬁbrillation for
several years. He was admitted to our hospital on December 15,
2009 due to a 1-week history of intermittent tarry stools. He also
had epigastric pain, acid reﬂux, and a 3-kg weight loss over
1 month.erest.
3, Changsha Street, Taitung,
ir).
iwan Society of Geriatric EmergenThe initial physical examination was unremarkable except for
epigastric pain on pressure and pale conjunctivae. His hemoglobin
was 61 g/L (normal: 115e150 g/d), hematocrit 0.19 (normal:
0.35d0.47), and albumin 31 g/L(normal: 35e50 g/L). Hypona-
tremia (133 mmol/L; normal: 135e147 mmol/L) and hypouricemia
(208 mmol/L; normal 262e452 mmol/L) were also noted. The tumor
markers carbohydrate antigen 19-9 and alpha fetoprotein were
both within the normal range, but carcinoembryonic antigen level
was 249.40 mg/L (normal <3.4 mg/L).
Initial treatment included blood transfusion, electrolyte
support, and high-dose intravenous proton pump inhibitors. Upper
gastrointestinal endoscopy revealed a large stage A2 ulcer on the
greater curvature of the gastric body. Pathological ﬁndings from
biopsy specimens revealed small-sized tumor cells composed of
irregular hyperchromatic nuclei with scant cytoplasm (Figs. 1 and
2). The tumor cells stained positive for cytokeratin, synaptophy-
sin, and chromogranin (Figs. 3 and 4). Based on the histological
ﬁndings and immunohistochemical presentation, the diagnosis of
SmCC was conﬁrmed.
Contrast-enhanced computed tomography scanning showed
irregular lobulated wall thickening of the gastric fundus and body,
with inﬁltrative low attenuation. No tumors were found in other
organs, including the lungs, nor was lymphadenopathy found on
computed tomography scans. The clinical diagnosis based on these
ﬁndings was primary SmCC of the stomach. The patient declined
further evaluation and received palliative treatment.cy & Critical Care Medicine. Published by Elsevier Taiwan LLC. All rights reserved.
Fig. 1. Histological appearance of small-cell carcinoma of the stomach. The normal
gastric mucosal architecture has been nearly completely replaced by the tumor. Tumor
cells have darkly staining oval to spindle-shaped nuclei and extremely scanty cyto-
plasm (H&E stain, 10).
Fig. 3. Microscopic view of the gastric small-cell carcinoma biopsy specimen, showing
positive staining for synaptophysin (40).
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The vast majority of SmCC develop from the lung, with only 2.5%
presenting at extrapulmonary sites, including the esophagus,
stomach, colon, pancreas, pharynx, bladder, and uterine cervix7,8.
Primary gastric SmCC was ﬁrst reported in 1976 and accounts for
only 11% of all gastrointestinal SmCC9. The incidence of gastric
carcinoma is higher in Asia than in Western countries, but primary
gastric SmCC is still rare. One recent study presented the clinico-
pathological characteristics of gastric SmCC in 213 patients10. Of
these cases, 78.9% developed in males and 21.1% in females. The age
of patients ranged from 28 to 89 years, with a mean of 65.1 years.
Fifteen cases of the tumor were limited to the mucosa or submu-
cosa, whereas 112 cases presented in an advanced stage. Median
survival time was only 9 months (range 0e96 months).
The histological features of gastric SmCC are similar to those of
pulmonary SmCC, with solid, organoid, trabecular, and pseudo-
glandular patterns. The tumor cells demonstrate a high nuclear
grade, with minimal cytoplasm, indistinct nucleoli and nuclear
molding11. Microscopically, gastric SmCC are of two types: (1) pure
type, accounting for 60% of the total2,4, and (2) composite type, with
glandular or squamous differentiation3.Fig. 2. Microscopic view of the gastric small-cell carcinoma, showing tumor cells with
a high nuclear grade, minimal cytoplasm, “salt and pepper”-like chromatin, indistinct
nucleoli, and nuclear molding (H&E stain, 40).Since primary SmCC of the stomach is as aggressive as SmCC of
the lung, the prognosis is extremely poor. Local nodal involvement
and distant metastasis are frequent presentations, even at an early
clinical stage. Primary gastric SmCC has nonspeciﬁc clinical mani-
festations, and the laboratory ﬁndings are similar to those of other
gastric carcinoma. Therefore, it is difﬁcult to diagnose preopera-
tively, and a deﬁnitive diagnosis requires both histological features
and immunohistochemical presentation. In one study of 15
reported cases, only six (40%) were diagnosed correctly before
surgery7. Gastric SmCC has a similar immunohistochemical
presentation to that of lung SmCC, but is distinct for its positive
reaction to chromogranin-A, synaptophysin, neuron-speciﬁc
enolase, CD56, and S-100 protein5,9. In our patient, the immuno-
histochemical examination showed positive expression of keratin
and two neuroendocrine markers e chromogranin-A and syn-
aptophysin e conﬁrming the diagnosis of SmCC.
The standard therapy for primary SmCC of stomach has not yet
been established. Operation and operation with adjuvant chemo-
therapy are the most used therapies reported. In one study using
chemotherapy alone in patients with primary gastric SmCC, car-
boplatin and etoposide were used in the salvage regimens usually
applied to patients with small-cell lung cancer, and a longermedian
survival time (over 12months) was observed10,12e14. Therefore, thisFig. 4. Microscopic view of the gastric small-cell carcinoma biopsy specimen, showing
positive staining for chromogranin A (40).
Primary Gastric Small Cell Carcinoma 51chemotherapy regimen may provide a survival beneﬁt for patients
with primary gastric SmCC and distant metastases. Surgery may
beneﬁt patients who do not have distant metastases10.
Tegafur/gimeracil/oteracil potassium, or S-1-based chemo-
therapy, is the most effective regiment for adjuvant chemotherapy
for primary gastric SmCC12. Thus, S-1 may improve the prognosis
for patients with primary gastric SmCC15. Larger studies are needed
to conﬁrm this ﬁnding.
In conclusion, gastric SmCC is a rare tumor appearing mostly in
older adults, especially males. It has nonspeciﬁc clinical manifes-
tations, and the parameters, including tumor markers and imaging
studies, cannot be used alone to reliably establish a preoperative
diagnosis. Histological features and immunohistochemical exami-
nation together are required for a deﬁnitive diagnosis. The standard
treatment has not been established, and larger trials are needed to
determine the best treatment for gastric SmCC. This rare gastric
tumor should be listed in the differential diagnosis of gastric
carcinoma in older adults.References
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